FI3866931T3 - Deuteriumia sisältäviä yhdisteitä - Google Patents
Deuteriumia sisältäviä yhdisteitä Download PDFInfo
- Publication number
- FI3866931T3 FI3866931T3 FIEP19790194.5T FI19790194T FI3866931T3 FI 3866931 T3 FI3866931 T3 FI 3866931T3 FI 19790194 T FI19790194 T FI 19790194T FI 3866931 T3 FI3866931 T3 FI 3866931T3
- Authority
- FI
- Finland
- Prior art keywords
- mol
- deuterium
- compound according
- compound
- abundance level
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 26
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 title claims 15
- 229910052805 deuterium Inorganic materials 0.000 title claims 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 229940124622 immune-modulator drug Drugs 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1816998.7A GB201816998D0 (en) | 2018-10-18 | 2018-10-18 | Compounds |
| GBGB1909695.7A GB201909695D0 (en) | 2019-07-05 | 2019-07-05 | Compounds |
| PCT/EP2019/078250 WO2020079165A1 (en) | 2018-10-18 | 2019-10-17 | Compounds containing deuterium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3866931T3 true FI3866931T3 (fi) | 2023-05-10 |
Family
ID=68290247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP19790194.5T FI3866931T3 (fi) | 2018-10-18 | 2019-10-17 | Deuteriumia sisältäviä yhdisteitä |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US12152087B2 (enExample) |
| EP (1) | EP3866931B1 (enExample) |
| JP (2) | JP7603199B2 (enExample) |
| KR (1) | KR102848971B1 (enExample) |
| CN (1) | CN112930214B (enExample) |
| AU (1) | AU2019362389B2 (enExample) |
| BR (1) | BR112021007060A2 (enExample) |
| CA (1) | CA3116198A1 (enExample) |
| DK (1) | DK3866931T3 (enExample) |
| ES (1) | ES2942468T3 (enExample) |
| FI (1) | FI3866931T3 (enExample) |
| HU (1) | HUE061801T2 (enExample) |
| IL (1) | IL282231B2 (enExample) |
| MA (1) | MA53904A (enExample) |
| MX (1) | MX2021004474A (enExample) |
| PL (1) | PL3866931T3 (enExample) |
| SG (1) | SG11202103726RA (enExample) |
| WO (1) | WO2020079165A1 (enExample) |
| ZA (1) | ZA202102492B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201905477D0 (en) * | 2019-04-17 | 2019-05-29 | Oncopeptides Ab | Novel formulations |
| ES3034388T3 (en) * | 2021-06-01 | 2025-08-18 | Synthon Bv | Process for making melflufen or a salt thereof |
| JP2024524552A (ja) | 2021-07-08 | 2024-07-05 | オンコペプティデス エービー | 多発性骨髄腫の治療に使用するためのメルフルフェン |
| GB202109894D0 (en) | 2021-07-08 | 2021-08-25 | Oncopeptides Ab | Novel treatments |
| GB202109896D0 (en) | 2021-07-08 | 2021-08-25 | Oncopeptides Ab | Novel treatments |
| GB202109895D0 (en) | 2021-07-08 | 2021-08-25 | Oncopeptides Ab | Novel treatments |
| GB202204171D0 (en) | 2022-03-24 | 2022-05-11 | Oncopeptides Ab | Novel formulations |
| WO2026057823A1 (en) * | 2024-09-13 | 2026-03-19 | Oncopeptides Ab | Bis-chloroethylamino derivatives for treating leukemia |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0002202D0 (sv) | 2000-06-13 | 2000-06-13 | Karolinska Innovations Ab | New peptides |
| CA2972242A1 (en) | 2008-09-18 | 2010-04-22 | Auspex Pharmaceuticals, Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| EP3351247A1 (en) | 2010-06-01 | 2018-07-25 | Auspex Pharmaceutical, Inc. | Benzoquinolone inhibitors of vmat2 |
| DK2701720T3 (en) * | 2011-04-28 | 2017-10-09 | Oncopeptides Ab | Lyophilized preparation with cytotoxic dipeptides |
| EP4345100A3 (en) | 2012-09-18 | 2024-04-10 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| SMT202000058T1 (it) * | 2012-10-26 | 2020-03-13 | Oncopeptides Ab | Preparazioni liofilizzate di melfalan flufenammide |
| JP2016506957A (ja) | 2013-01-31 | 2016-03-07 | オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｖｍａｔ２のベンゾキノロン阻害剤 |
| ES2901752T3 (es) * | 2013-02-05 | 2022-03-23 | Teva Pharmaceuticals Int Gmbh | Derivados de catecolamina enriquecidos con deuterio asimétrico de posición específica y medicamentos que comprenden dichos compuestos |
| WO2015084622A1 (en) | 2013-12-03 | 2015-06-11 | Auspex Pharmaceuticals, Inc. | Methods of manufacturing benzoquinoline compounds |
| CN110229159B (zh) | 2013-12-18 | 2021-08-24 | 康塞特医药品有限公司 | 卢索替尼的氘代衍生物 |
| AU2016229949B2 (en) | 2015-03-06 | 2021-04-08 | Auspex Pharmaceuticals Llc | Methods for the treatment of abnormal involuntary movement disorders |
| GB201507903D0 (en) | 2015-05-08 | 2015-06-24 | Oncopeptides Ab | Process for preparation of nitrogen mustard derivatives |
| GB201521217D0 (en) * | 2015-12-01 | 2016-01-13 | Oncopeptides Ab | Dosage regimens |
-
2019
- 2019-10-17 US US17/286,002 patent/US12152087B2/en active Active
- 2019-10-17 SG SG11202103726RA patent/SG11202103726RA/en unknown
- 2019-10-17 WO PCT/EP2019/078250 patent/WO2020079165A1/en not_active Ceased
- 2019-10-17 HU HUE19790194A patent/HUE061801T2/hu unknown
- 2019-10-17 FI FIEP19790194.5T patent/FI3866931T3/fi active
- 2019-10-17 MX MX2021004474A patent/MX2021004474A/es unknown
- 2019-10-17 MA MA053904A patent/MA53904A/fr unknown
- 2019-10-17 IL IL282231A patent/IL282231B2/en unknown
- 2019-10-17 DK DK19790194.5T patent/DK3866931T3/da active
- 2019-10-17 KR KR1020217011490A patent/KR102848971B1/ko active Active
- 2019-10-17 CN CN201980068384.1A patent/CN112930214B/zh active Active
- 2019-10-17 EP EP19790194.5A patent/EP3866931B1/en active Active
- 2019-10-17 ES ES19790194T patent/ES2942468T3/es active Active
- 2019-10-17 PL PL19790194.5T patent/PL3866931T3/pl unknown
- 2019-10-17 JP JP2021521145A patent/JP7603199B2/ja active Active
- 2019-10-17 CA CA3116198A patent/CA3116198A1/en active Pending
- 2019-10-17 AU AU2019362389A patent/AU2019362389B2/en active Active
- 2019-10-17 BR BR112021007060-5A patent/BR112021007060A2/pt unknown
-
2021
- 2021-04-15 ZA ZA2021/02492A patent/ZA202102492B/en unknown
-
2024
- 2024-07-03 JP JP2024107578A patent/JP2024150488A/ja active Pending
- 2024-10-16 US US18/917,773 patent/US20250115637A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7603199B2 (ja) | 2024-12-20 |
| CN112930214A (zh) | 2021-06-08 |
| MX2021004474A (es) | 2021-08-24 |
| EP3866931B1 (en) | 2023-02-15 |
| IL282231A (en) | 2021-05-31 |
| MA53904A (fr) | 2021-08-25 |
| ES2942468T3 (es) | 2023-06-01 |
| KR102848971B1 (ko) | 2025-08-21 |
| US20250115637A1 (en) | 2025-04-10 |
| HUE061801T2 (hu) | 2023-08-28 |
| BR112021007060A2 (pt) | 2021-07-20 |
| KR20210078487A (ko) | 2021-06-28 |
| EP3866931A1 (en) | 2021-08-25 |
| IL282231B2 (en) | 2025-07-01 |
| US12152087B2 (en) | 2024-11-26 |
| JP2024150488A (ja) | 2024-10-23 |
| CN112930214B (zh) | 2025-05-16 |
| US20210388024A1 (en) | 2021-12-16 |
| AU2019362389A1 (en) | 2021-06-03 |
| WO2020079165A1 (en) | 2020-04-23 |
| IL282231B1 (en) | 2025-03-01 |
| JP2022512736A (ja) | 2022-02-07 |
| PL3866931T3 (pl) | 2023-06-19 |
| DK3866931T3 (da) | 2023-04-24 |
| CA3116198A1 (en) | 2020-04-23 |
| SG11202103726RA (en) | 2021-05-28 |
| ZA202102492B (en) | 2024-04-24 |
| AU2019362389B2 (en) | 2024-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3866931T3 (fi) | Deuteriumia sisältäviä yhdisteitä | |
| PH12022552410A1 (en) | Biaryl derivatives as yap/taz-tead protein-protein interaction inhibitors | |
| HRP20150744T4 (hr) | Modulatori farmakokinetičkih svojstava lijekova | |
| DE60010076D1 (de) | Chinolinderivate als antibakterielle mittel | |
| NO20040954L (no) | Benzotiazepinderivater for behandling av hyperlipidemi | |
| EA200701902A1 (ru) | Бициклические [3.1.0] гетероариламиды в качестве ингибиторов переноса глицина типа i | |
| WO2005054179A3 (en) | Hydroxamic acid esters and pharmaceutical use thereof | |
| NO20040924L (no) | Benzotiazepinderivater. | |
| WO2012007869A3 (en) | N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels | |
| BR0210504A (pt) | Derivados de naftil-indol substituidos, atuantes como inibidores do inibidor tipo 1 (pai-1) do ativador de plasminogênio | |
| BR112014019478A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmacologicamente aceitável do mesmo, formulação inibidor do canal de sódio, métodos para tratamento e/ou prevenção de dor e de uma doença. | |
| PH12012501881A1 (en) | 4-amino-4- oxobutanoyl peptides as inhibitors of viral replication | |
| GB0114286D0 (en) | Nucleoside Derivatives | |
| MXPA02012034A (es) | Derivados de tiofeno utiles como agentes anticancerosos. | |
| HRP20120310T1 (hr) | Derivati benzazepina korisni kao antagonisti vazopresina | |
| BR0207846A (pt) | Derivados heterocìclicos para o tratamento de câncer e outras doenças proliferativas | |
| MY195177A (en) | Pyrazole Derivative or Pharmaceutically Acceptable Salt Thereof | |
| RU2005111590A (ru) | 2,4-замещенные индолы и их использование в качестве модуляторов 5-гт6 | |
| SE0002476D0 (sv) | New compounds | |
| GEP20115222B (en) | New pharmaceutical compounds | |
| IL160082A0 (en) | Quinoline derivatives and use thereof as antitumor agents | |
| BRPI0409217A (pt) | derivados e análogos antimicrobianos da [3.1.0]bicicloexilfeniloxazolidinona | |
| JP2004504377A5 (enExample) | ||
| TW200626567A (en) | Benzoxazine and quinoxaline derivatives and uses | |
| TW201129557A (en) | Pharmaceutical composition for oral administration |